Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  Culturally Aware CarePreventionPublic HealthIssue 619

Peer Mentoring Helps Reduce A1c a Full Point

Talking with diabetic peers who've gotten their blood sugar under control helped other African-American diabetes patients bring down their own levels a full point, more than those who were offered $100 to reduce their A1c 1 point or even $200 to reduce their A1c 2 points....

Advertisement

Judith Long, MD, of the University of Pennsylvania, and colleagues reported in the March 20 issue of Annals of Internal Medicine that in a sixth-month intervention among black veterans, those in a peer mentoring program lowered their HbA1c levels more than either those on usual care or those given a financial incentive.

They wrote, "On average, patients in the peer mentor group decreased their HbA1c levels by close to 1% compared with the control group, whereas patients in the financial incentive group decreased their levels by just 0.5% compared with the control group."

Diabetes is more common and more severe in African Americans, which makes them an important target for specific glucose control programs, the researchers said.

While the lifestyle and dietary changes that are required for successful HbA1c lowering are challenging, prior studies have shown that both peer support and financial incentives can help motivate patients.

So Long and colleagues conducted a six-month study among 118 patients at the Philadelphia Veterans Affairs Medical Center who hadn't been successful at lowering their HbA1c. Patients were assigned to one of three groups: usual care, peer mentoring, or a financial incentive.

The usual care group was solely given specific goals for HbA1c control, while those in the peer mentoring group were connected with another diabetes patient who once had poor glucose control but had brought it to a target level (mean 6.7% at baseline). Mentors and mentees were told to speak at least once per week, and mentors were paid $20 for the trial.

Those in the financial incentive group could earn $100 by dropping their HbA1c levels by 1%, or $200 if they lowered them by 2% or hit 6.5% or lower.

Long and colleagues found that patients who spoke with a peer mentor on a weekly basis achieved the greatest declines in blood sugar. HbA1c fell from 9.9% to 9.8% among controls, from 9.8% to 8.7% among those with peer mentors, and from 9.5% to 9.1% in the financial incentive group.

Compared with the usual care group, the mean change in HbA1c from baseline to six months was -1.07% for those in the peer mentoring group and -0.45% for those in the financial incentive group.

The decline in HbA1c achieved in the financial incentive group wasn't clinically significant, but confidence intervals were wide so it's not conclusive that the intervention was ineffective, the researchers said. They also found that mentors and mentees spoke most frequently in the first month, with a mean of four calls per month, dropping off to a mean of two per month by the end of the trial. It's not clear whether fewer calls reflect reduced motivation or a perceived decrease in need, they noted.

Patients in the mentoring group likely benefitted from a culture of camaraderie, specifically because all patients were veterans, the researchers said -- so a similar culture may not be cultivated among other diabetic groups.

The intervention was also likely a success because the "long history of mistreatment and distrust in the healthcare system may make peer support particularly effective for African Americans," they wrote.

"Perhaps the most obvious attraction of this type of peer mentoring is that it is virtually free, almost certainly enhancing its cost-effectiveness relative to more expensive interventions, such as nurse care management, telemedicine, and group medical appointments," they added.

Long and colleagues called for future studies to determine whether the effects are sustainable, noting that one possible approach to maintaining its effects would be to transition patients who achieve good control from mentee to mentor roles.

Practice Pearls:
  • Note that the decline in A1c achieved in the financial incentive group wasn't clinically significant, but confidence intervals were wide so it's not conclusive that the intervention was ineffective.
  • Note that mentoring by diabetic peers who were successful in controlling their blood sugar helped other African-American diabetes patients bring down their own level.

Long JA, et al "Peer mentoring and financial incentives to improve glucose control in African American veterans" Ann Intern Med 2012; 156: 416-424.

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 27 March, 2012 and appeared in  Culturally Aware CarePreventionPublic HealthIssue 619

Past five issues: Issue 766 | Diabetes Clinical Mastery Series Issue 225 | Issue 765 | Diabetes Clinical Mastery Series Issue 224 | Issue 764 |

2014 Most Popular Articles:

Significant Weight Loss and Drop in A1c with New Combo of Lorcaserin and Phentermine
Posted January 16, 2015
ADA Issues New Standards of Medical Care for Diabetes
Posted January 02, 2015
New Guideline Released on Pharmacological Management of Obesity
Posted January 23, 2015
Dr. Timothy Garvey on Qsymia and Other New Therapies for Weight Loss
Posted January 12, 2015
Handbook of Diabetes, 4th Ed., Excerpt #25: Specific Circumstances that Affect Diabetes Control
Posted January 04, 2015
For Your Patients: Practical Advice to Rev Up Your Workouts and Lower Fatigue
Posted January 09, 2015
Phentermine and Topirimate ER (Qsymia) Studied for Type 2 Diabetes Patients
Posted January 15, 2015
New Guidelines Recommend Off-Loading to Increase Likelihood of Diabetic Foot Ulcer Healing
Posted December 26, 2014
New Insulin Glargine 300 Effective in Type 1 Diabetes
Posted January 16, 2015
FDA Approves Weight-management Drug Saxenda
Posted December 26, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Will you prescribe inhaled insulin (Afrezza) when it becomes available this year?
Search Articles On Diabetes In Control